Tagged with B

Global Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some of Astellas’ work with patient advocacy groups to generate these insights, why a new era of real-world data (RWD) generation…

Global Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time in high-income countries, the developing world risks falling behind. Less than ten percent of the African continent has been vaccinated,…

Saudi Arabia Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across pharma distribution through SITCO Pharma, manufacturing (both for its own products and as a contract manufacturing organisation (CMO)) via AJA…

Global As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better understand their needs. However, as the below insights from four of Novartis Oncology’s patient engagement leads show, successfully integrating patient…

MEA Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma executives overseeing his region need to succeed.   As region head for a company that is only 40 years old,…

Global One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems so great, but the evidence remains so patchy.   So far, top tier regulators such as the US FDA and…

Saudi Arabia While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly fit for purpose.   Oscar Delgado of BMS is one such stakeholder. “An adequate IP system, including regulatory data protection…

Global Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left…

Saudi Arabia Before Crown Prince Mohammed bin Salman assumed office in 2017, Saudi Arabian women had only a marginal presence in the Kingdom’s labour force. However, since then notable milestones achieved include granting women the right to drive, access to sports, a first female ambassador, freedom to travel, the right to live…

Spain The executive president of Laboratorios Rubió, Carlos Rubió, analyses the fundamentals behind the Catalan company’s double-digit growth, its international expansion plan, which includes the United States, the doubling of capacity at their Castellbisbal plant, and the challenges of the Spanish market. A producer of hydroxychloroquine, Laboratorios Rubió experienced skyrocketing demand…

China Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s reimbursement list in 2021; the former GSK scientist pleading guilty to stealing trade secrets for Chinese pharma; and BioNTech’s continuing…

Saudi Arabia The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to Market Research Future. Like other parts of the Saudi healthcare continuum, the country’s medtech industry is extremely dynamic and changing…